Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: A multi-institute retrospective study

Gastric Cancer

Volumn 15, Issue 3, 2012, Pages 235-244

  Kanda, Tatsuo ^a   Yajima, Kazuhito ^a   Kosugi, Shin Ichi ^a   Ishikawa, Takashi ^a   Ajioka, Yoichi ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Prognosis; S 1; Secondary surgery

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL; TS 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DRUG ERUPTION; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; LAPAROTOMY; MALE; MULTIVARIATE ANALYSIS; OXONIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84865444726     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0100-y     Document Type: Article

References (23)

1. Parkin DM. Global cancer statistics. 2000. CA cancer J Clin. 2005;55:74-108.
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Cons-tenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagoga-stric cancer. N Engl J Med. 2008;358:36-46.
4. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1M tegaful-0.4M 5-chloro-2, 4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602-6.
5. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715-20.
6. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, etal. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207-12.
7. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol. 2009;10:1063-9.
8. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
9. Ishigami S, Natsugoe S, Nakajo A, Matsumoto M, Uenosono Y, Arigami T, et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer. J Gas-trointest Surg. 2008;12:1370-5.
10. Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, et al. Phase I and pharmacokinetic study of S-1 com-bined with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 2005;69:414-20.
11. Takiuchi H, Narahara H, Tsujinaka T, Gotoh M, Kawabe S, Katsu K, et al. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol. 2005;35:520-5.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
13. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma\2nd English Edition\response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer. 2001;4:1-8.
14. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 99-103.
15. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 13th ed. Tokyo: Kanehara & co., Ltd.; 1998 (in Japanese).
16. Ohashi M, Kanda T, Kobayashi T, Hirota M, Hayami M, Yajima K, et al. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer. Hepatogastroenterology. 2011;58:652-8.
17. Iwahashi M, Nakamori M, Tani M, Yamaue H, Sakaguchi S, Nakamura M, et al. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined che-motherapy of S-1 and low-dose cisplatin: report of a case. Oncology. 2001;61:16-22.
18. Yoshimizu N, Saikawa Y, Kubota T, Yoshimizu N, Saikawa Y, Kubota T, et al. Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. Gastric Cancer. 2003;6:185-90.
19. Yoshida I, Sakurai Y, Komori Y, Tonomura S, Masui T, Shoji M, et al. Successful downstaging by S-1-based chemotherapy fol-lowed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis\report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy. Hepatogastroenterology. 2005;52:978-84.
20. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hir-atsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy: Japan Clinical Oncology Group Study 9501. J Clin Oncol. 2004;22:2767-73.
21. Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643-9.
22. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995-9.
23. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Otsuo T. Preoperative chemotherapy S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res. 2009;29:4689-96.